Kalia LV, Lang AE. Parkinson disease in 2015: evolving basic, pathological and clinical concepts in pd. Nat Rev Neurol. 2016;12(2):65–6.

Article  CAS  PubMed  Google Scholar 

Schapira A, Chaudhuri KR, Jenner P. Non-motor features of parkinson disease. Nat Rev Neurosci. 2017;18(7):435–50.

Article  CAS  PubMed  Google Scholar 

Mensikova K, Steele JC, Rosales R, Colosimo C, Spencer P, Lannuzel A, et al. Endemic parkinsonism: clusters, biology and clinical features. Nat Rev Neurol. 2023;19(10):599–616.

Article  PubMed  Google Scholar 

Taguchi K, Watanabe Y, Tsujimura A, Tanaka M. Brain region-dependent differential expression of alpha-synuclein. J Comp Neurol. 2015: n/a-n/a

Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013;79(6):1044–66.

Article  CAS  PubMed  Google Scholar 

Yasuda T, Nakata Y, Mochizuki H. Alpha-synuclein and neuronal cell death. Mol Neurobiol. 2013;47(2):466–83.

Article  CAS  PubMed  Google Scholar 

Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. J Parkinsons Dis. 2017;7(s1):S53–71.

Google Scholar 

Wong YC, Krainc D. Alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23(2):1–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, Ueda K, et al. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a c-terminal specific monoclonal antibody. Brain Res. 2008;1244:40–52.

Article  CAS  PubMed  Google Scholar 

Koss DJ, Erskine D, Porter A, Palmoski P, Menon H, Todd OGJ et al. Nuclear alpha-synuclein is present in the human brain and is modified in dementia with lewy bodies. Acta Neuropathol Commun. 2022;10(1).

Zhou M, Xu S, Mi J, Uéda K, Chan P. Nuclear translocation of alpha-synuclein increases susceptibility of mes23.5 cells to oxidative stress. Brain Res. 2013;1500:19–27.

Article  CAS  PubMed  Google Scholar 

Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of parkinson’s disease: involvement of alpha-synuclein. Neurotox Res. 2010;17(2):130–41.

Article  CAS  PubMed  Google Scholar 

Siddiqui A, Chinta SJ, Mallajosyula JK, Rajagopolan S, Hanson I, Rane A, et al. Selective binding of nuclear alpha-synuclein to the pgc1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for parkinson’s disease. Free Radic Biol Med. 2012;53(4):993–1003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, et al. Subcellular localization of wild-type and parkinson’s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci. 2000;20(17):6365–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma KL, Song LK, Yuan YH, Zhang Y, Han N, Gao K, et al. The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. Neuropharmacology. 2014;82:132–42.

Article  CAS  PubMed  Google Scholar 

Pinho R, Paiva I, Jercic KG, Fonseca-Ornelas L, Gerhardt E, Fahlbusch C et al. Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Hum Mol Genet. 2018.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P et al. Trim28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. Elife. 2016;5.

Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, Schoepfer R. Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell Neurosci. 2005;28(2):326–34.

Article  CAS  PubMed  Google Scholar 

Zhong SC, Luo X, Chen XS, Cai QY, Liu J, Chen XH, et al. Expression and subcellular location of alpha-synuclein during mouse-embryonic development. Cell Mol Neurobiol. 2010;30(3):469–82.

Article  CAS  PubMed  Google Scholar 

Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, Kiely A, et al. The novel parkinson’s disease linked mutation g51d attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet. 2014;23(17):4491–509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006;15(20):3012–23.

Article  CAS  PubMed  Google Scholar 

Miller RM, Kiser GL, Kaysser-Kranich T, Casaceli C, Colla E, Lee MK, et al. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of pd. Exp Neurol. 2007;204(1):421–32.

Article  CAS  PubMed  Google Scholar 

Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, Mclean PJ, Hyman BT, et al. Transcriptional dysregulation in a transgenic model of parkinson disease. Neurobiol Dis. 2008;29(3):515–28.

Article  CAS  PubMed  Google Scholar 

Vasquez V, Mitra J, Hegde PM, Pandey A, Sengupta S, Mitra S, et al. Chromatin-bound oxidized alpha-synuclein causes strand breaks in neuronal genomes in in vitro models of parkinson’s disease. J Alzheimers Dis. 2017;60(s1):S133–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goers J, Manning-Bog AB, Mccormack AL, Millett IS, Doniach S, Di Monte DA, et al. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry. 2003;42(28):8465–71.

Article  CAS  PubMed  Google Scholar 

Liu X, Lee YJ, Liou LC, Ren Q, Zhang Z, Wang S, et al. Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast. Hum Mol Genet. 2011;20(17):3401–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma KL, Song LK, Yuan YH, Zhang Y, Yang JL, Zhu P, et al. Alpha-synuclein is prone to interaction with the gc-box-like sequence in vitro. Cell Mol Neurobiol. 2014;34(4):603–9.

Article  CAS  PubMed  Google Scholar 

Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW et al. Alpha-synuclein is a dna binding protein that modulates dna repair with implications for lewy body disorders. Sci Rep. 2019;9(1).

Arawaka S, Sato H, Sasaki A, Koyama S, Kato T. Mechanisms underlying extensive ser129-phosphorylation in α-synuclein aggregates. Acta Neuropathol Commun. 2017;5(1).

Delenclos M, Faroqi AH, Yue M, Kurti A, Castanedes-Casey M, Rousseau L, et al. Neonatal aav delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun. 2017;5(1):51.

Article  PubMed  PubMed Central  Google Scholar 

Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012;124(1):37–50.

Article  CAS  PubMed  Google Scholar 

Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. 2018;128(4):1208–16.

Article  PubMed  PubMed Central  Google Scholar 

Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, et al. Aging and parkinson’s disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med. 2018;115:80–91.

Article  CAS  PubMed  Google Scholar 

Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.

Article  Google Scholar 

Uff C, Patel K, Yeung C, Yip PK. Advances in visualizing microglial cells in human central nervous system tissue. Biomolecules. 2022;12(5).

Lier J, Streit WJ, Bechmann I. Beyond activation: characterizing microglial functional phenotypes. Cells. 2021;10(9):2236.

Article  CAS